These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 16541250

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
    Laufer S, Hauser D, Stegmiller T, Bracht C, Ruff K, Schattel V, Albrecht W, Koch P.
    Bioorg Med Chem Lett; 2010 Nov 15; 20(22):6671-5. PubMed ID: 20934337
    [Abstract] [Full Text] [Related]

  • 23. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
    Jiang MN, Zhou XP, Sun DR, Gao H, Zheng QC, Zhang HX, Liang D.
    J Biomol Struct Dyn; 2018 Nov 15; 36(14):3705-3717. PubMed ID: 29064324
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
    Zhuo ZH, Sun YZ, Jin PN, Li FY, Zhang YL, Wang HL.
    Mol Biosyst; 2016 Jul 19; 12(8):2532-40. PubMed ID: 27263470
    [Abstract] [Full Text] [Related]

  • 27. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA, Hauser DR, Domeyer DM, Kinkel K, Liedtke AJ.
    J Med Chem; 2008 Jul 24; 51(14):4122-49. PubMed ID: 18578517
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC, Lin CY, Chi HC, Hwang CS, Chen TS, Tang CY, Hsiao NW.
    J Chem Inf Model; 2012 Jan 23; 52(1):146-55. PubMed ID: 22142286
    [Abstract] [Full Text] [Related]

  • 32. Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model.
    Kolb P, Huang D, Dey F, Caflisch A.
    J Med Chem; 2008 Mar 13; 51(5):1179-88. PubMed ID: 18271520
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Residue-ligand interaction energy (ReLIE) on a receptor-dependent 3D-QSAR analysis of S- and NH-DABOs as non-nucleoside reverse transcriptase inhibitors.
    de Brito MA, Rodrigues CR, Cirino JJ, Araújo JQ, Honório T, Cabral LM, de Alencastro RB, Castro HC, Albuquerque MG.
    Molecules; 2012 Jun 25; 17(7):7666-94. PubMed ID: 22732882
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.
    Divya V, Pushpa VL, Sarithamol S, Manoj KB.
    J Mol Graph Model; 2018 Jun 25; 82():48-58. PubMed ID: 29680736
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors.
    Bolós J.
    Mini Rev Med Chem; 2005 Sep 25; 5(9):857-68. PubMed ID: 16178727
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.